

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>SVF Investments (UK) Ltd</u> (Last) (First) (Middle) <u>69 GROSVENOR STREET</u> (Street) <u>LONDON X0 W1K 3JP</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Arbutus Biopharma Corp [ABUS]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>10/16/2017</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Participating Convertible Preferred Shares	\$7.13 ⁽¹⁾⁽²⁾	10/16/2017		P		500,000 ⁽¹⁾⁽²⁾		(1)(2)	10/16/2021 ⁽¹⁾⁽²⁾	Common shares, no par value	9,808,386 ⁽¹⁾⁽²⁾	\$100 ⁽¹⁾⁽²⁾	500,000	I	See footnotes ⁽³⁾⁽⁴⁾⁽⁵⁾

1. Name and Address of Reporting Person*
SVF Investments (UK) Ltd
 (Last) (First) (Middle)
69 GROSVENOR STREET
 (Street)
LONDON X0 W1K 3JP
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
SoftBank Vision Fund L.P.
 (Last) (First) (Middle)
69 GROSVENOR STREET
 (Street)
LONDON X0 W1K 3JP
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
SVF Holdings (UK) LLP
 (Last) (First) (Middle)
69 GROSVENOR STREET
 (Street)
LONDON X0 W1K 3JP
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
SVF GP (Jersey) Ltd
 (Last) (First) (Middle)
AZTEC GROUP HOUSE
11-15 SEATON PLACE

